Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + nab-paclitaxel + platinum-based chemotherapy
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination regimen is a chemoimmunotherapy induction therapy primarily used in the neoadjuvant setting for locally advanced thoracic esophageal squamous cell carcinoma (ESCC). It consists of **toripalimab**, a humanized IgG4 monoclonal antibody that targets the Programmed Cell Death Protein 1 (PD-1) receptor to enhance T-cell anti-tumor activity; **nab-paclitaxel** (albumin-bound paclitaxel), a microtubule inhibitor that disrupts mitotic spindle formation; and a **platinum-based chemotherapy** agent (such as cisplatin or carboplatin) that induces DNA cross-linking and subsequent apoptosis. The regimen is currently being evaluated in Phase III clinical trials to determine if patients achieving a clinical response can undergo organ preservation via radical chemoradiotherapy as an alternative to immediate radical esophagectomy.
- Brand names
- Tuoyi
- Other names
- toripalimab plus nab-paclitaxel and platinum-based chemotherapy
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on toripalimab + nab-paclitaxel + platinum-based chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + nab-paclitaxel + platinum-based chemotherapy.